BioSpace News Archive

The 2019 Annual Report contains HEXO’s 2019 annual information form and its audited financial statements and management’s discussion and analysis for the fiscal year ended July 31, 2019.

Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing.

Mark F. Kubik to Lead Business Development and Alliance Management Team

Zymeworks has become a “well-known seasoned issuer” under SEC rules and is filing the new Registration Statement to take advantage of certain benefits only available to WKSIs.

Sage Therapeutics, Inc. announced that on November 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 7,350 shares of its common stock, and 1,225 performance restricted stock units to three new employees under Sage’s 2016 Inducement Equity Plan.

The webcast will be recorded, and will be available for replay via the website until 5:00 p.m. Mountain Time on Friday, December 13, 2019.

The translates to 200,000 fewer deaths in 2016 than if mortality rates stayed the same as 2009.

Bringing 40 years of healthcare expertise and a fast growing network of quality care providers